This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019.

SAN FRANCISCO – Latanoprostene bunod showed greater reduction in intraocular pressure (IOP) after 3 months compared to other treatments for open-angle glaucoma and ocular hypertension, according to research presented at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, held October 12-15, 2019 in San Francisco, California.

Investigators conducted a network meta-analysis to compare the effectiveness of latanoprostene bunod against other prostaglandin analogue (PGA) therapies in terms of reducing IOP in open-angle glaucoma and ocular hypertension. They searched various databases and identified 104 studies involving 18,407 patients. The treatments were ranked by the surface under cumulative ranking rate (SUCRA).

Related Articles

Results showed that latanoprostene bunod was significantly more effective than apraclonidine, brimonidine, betaxolol, timolol, brinzolamide and dorzolamide. Numerically, compared with other PGAs, latanoprostene bunod demonstrated the greatest efficacy except when compared with bimatoprost 0.03%. Investigators found that among all treatments included in the analysis, bimatoprost 0.03% ranked the highest (SUCRA 94%), followed by latanoprostene bunod (88%), then bimatoprost 0.01% (83%). 

“[Latanoprostene bunod] numerically outranked the 3 most widely used PGAs, namely latanoprost, travoprost and bimatoprost 0.01%, in IOP reduction,” the investigators concluded. 

Related Articles

Latanoprostene bunod (Vyzulta) is a once-daily ophthalmic solution currently approved for the treatment of open-angle glaucoma and ocular hypertension. It is the first PGA to have nitric oxide as one of its metabolites. It exerts a dual mechanism of action through latanoprost acid, which works within the uveoscleral pathway to increase aqueous humor outflow, and through butanediol mononitrate, which releases nitric oxide to increase outflow through the trabecular meshwork and Schlemm’s canal.

Reference: 

Harasymowycz PJ, Royer C, Jobin Gervais K, et al. Effectiveness of latanoprostene bunod in treating OAG and OHT: network meta-analysis. Presented at: The American Academy of Ophthalmology (AAO) 2019 Annual Meeting; October 12-15, 2019; San Francisco, California. Abstract PO176.